DMT Clinical Trial

Cybin Inc's Two Deuterated Psychedelic Molecules Achieve Positive Topline Clinical Results
Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics
Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation
Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics
Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation
Cybin And Fluence Partner To Support EMBARK Training For Phase 3 CYB003 Trial For Depression
Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results

DMT Clinical Trial Recent News

DMT's Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up
Algernon Pharmaceuticals’ (OTCQB: AGNPF) wholly-owned Algernon NeuroScience (AGN Neuro) successfully completed dosing the third and final cohort of its Phase 1 clinical study assessing an intravenous (IV) formulation of the company’s DMT compound, AP-188, aiming to treat both stroke and Traumati
Novel DMT Compound For Anxiety Shows Clinical Progress: Robust Effects Within 2 Minutes
Canadian clinical-stage psychedelics company Cybin Inc. (NYSE: CYBN) announced that the first group of participants have been dosed with its proprietary deuterated DMT molecule, CYB004, in an ongoing
Atai Life Sciences Q1 2023 Results, Pipeline Update On DMT And Psilocybin Clinical Trials
Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) reported the financial results for its first quarter ended March 31, 2023, and provided the period’s business highlights. Consolidated quarterly financials:
This IV Psychedelic-Based Compound Completes Phase 2a Trial, Company Gets Extra IP Coverage
Short-acting psychedelics biotech company Small Pharma Inc.
Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon
Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc.
Next-Gen Psychedelic Delivers Promising Results For Treatment-Resistant Depression In Phase 2 Clinical Trial
Psychedelics biotech company Biomind Labs Inc. (OTC: BMNDF) has announced positive initial results from part 1 of a Phase 2 clinical trial on its proprietary liquid inhaled formulation of DMT, BMND01, designed for Treatment-Resistant Depression (TRD).
Tackling Depression With Psychedelics: New Phase 2 Clinical Study Begins At Yale University
Canadian-based psychedelics biopharma company Algernon Pharmaceuticals Inc.
atai's Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing
Clinical-stage biopharma company atai Life Sciences N.V. (NASDAQ: ATAI) has commenced dosing volunteers for its ongoing Phase 1 clinical study investigating its proprietary DMT-based VLS-01 for treatment-resistant depression (TRD). 
Clinical Study On DMT Inhaled Product For Treatment-Resistant Depression Completes Dosing Stage
Biomind Labs Inc. (OTC: BMNDF), a life sciences company developing medicinal next-generation psychedelics, completed the dose administration of 30 healthy subjects within its Phase 2 clinical trial of DMT-based proprietary drug BMND01 for the Treatment-Resistant Depression (TDR) disorder.
A Deeper Look At DMT Trials & Studies
This article by Elisabetta Fato was originally published on Microdose and appears here with permission.